profile-img
Jacob Berchuck

@jberchuck

Medical oncologist at @DanaFarber @HarvardMed focused on research and care for patients with genitourinary cancers. Husband | Dad | @LFC supporter.

calendar_today27-04-2009 04:18:22

236 Tweets

830 Followers

584 Following

Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

1/ 🚨Excited to share our 🆕 publication in Annals of Oncology:

The clinical landscape of cell-free DNA alterations in 1,671 patients with advanced biliary tract cancer

doi.org/10.1016/j.anno…

🧵👇

1/ 🚨Excited to share our 🆕 publication in Annals of Oncology: The clinical landscape of cell-free DNA alterations in 1,671 patients with advanced biliary tract cancer doi.org/10.1016/j.anno… 🧵👇
account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

2/
⭐️Highlights⭐️

🔎cfDNA data from 1,671 patients with advanced BTC
🎯Targetable genomic alterations (GA) detected in cfDNA in 44% of patients
🌎84% with any GA
🤝cfDNA-tissue concordance: ⬆️ IDH1 muts & BRAF V600E ⬇️ FGFR2 fusions
📉High cfDNA VAF a/w poor prognosis

Details👇

account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

3/
🎯Targeted therapies have transformed management of advanced BTC.

📸⬇️highlights National Comprehensive Cancer Network (NCCN) guideline-recommended treatments for molecularly-defined BTCs.

🩸🧬cfDNA analysis is an attractive approach for tumor genomic profiling that overcomes limitations of 💉🧬 tissue biopsy.

3/ 🎯Targeted therapies have transformed management of advanced BTC. 📸⬇️highlights @NCCN guideline-recommended treatments for molecularly-defined BTCs. 🩸🧬cfDNA analysis is an attractive approach for tumor genomic profiling that overcomes limitations of 💉🧬 tissue biopsy.
account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

4/
🔬We examined cfDNA as a tool to inform clinical management of patients with advanced BTC and generate novel insights into BTC tumor biology by analyzing NGS data of 2,068 cfDNA samples from 1,671 patients with advanced BTC from Guardant Health.

4/ 🔬We examined cfDNA as a tool to inform clinical management of patients with advanced BTC and generate novel insights into BTC tumor biology by analyzing NGS data of 2,068 cfDNA samples from 1,671 patients with advanced BTC from @GuardantHealth.
account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

5/
⭐️84% of BTC patients had at least one genomic alteration (GA) detected in cfDNA

🌟44% had a targetable (Level 1-3B) GA in cfDNA based on OncoKB™ classification

💫12% had a Level 1 GA in cfDNA ➡️ FDA-recognized biomarker predictive of response to an FDA-approved drug in BTC

5/ ⭐️84% of BTC patients had at least one genomic alteration (GA) detected in cfDNA 🌟44% had a targetable (Level 1-3B) GA in cfDNA based on @OncoKB classification 💫12% had a Level 1 GA in cfDNA ➡️ FDA-recognized biomarker predictive of response to an FDA-approved drug in BTC
account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

6/
📊Prevalence of specific alterations in cfDNA from patients with BTC that predict response to an FDA-approved therapy in BTC.

✅IDH1 muts 9.1%
✅FGFR2 fusions 1.4%
✅BRAF V600E 1.3%
✅NTRK fusions 0.1%
✅RET fusions 0.1%

6/ 📊Prevalence of specific alterations in cfDNA from patients with BTC that predict response to an FDA-approved therapy in BTC. ✅IDH1 muts 9.1% ✅FGFR2 fusions 1.4% ✅BRAF V600E 1.3% ✅NTRK fusions 0.1% ✅RET fusions 0.1%
account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

7/
📊Prevalence of alts that predict response to other FDA-approved therapies:

✅PIK3CA muts 6.8%
✅ERBB2 amps 4.9%
✅BRCA1/2 muts 1.8%
✅KRAS G12C 1.0%

🔑Manuscript includes supp table with frequency of all alts present in cfDNA from this BTC cohort. Impt for drug discovery!

7/ 📊Prevalence of alts that predict response to other FDA-approved therapies: ✅PIK3CA muts 6.8% ✅ERBB2 amps 4.9% ✅BRCA1/2 muts 1.8% ✅KRAS G12C 1.0% 🔑Manuscript includes supp table with frequency of all alts present in cfDNA from this BTC cohort. Impt for drug discovery!
account_circle
Jacob Berchuck(@jberchuck) 's Twitter Profile Photo

8/
To establish how well 🩸🧬 cfDNA recapitulates 💉🧬 tumor tissue, we compared the prevalence of mutations between the BTC cfDNA samples (N=1,671) with metastatic BTC tumor NGS data from AACR Project GENIE (N=349).

Correlation was impressively high ⬆️ (R2=0.96)‼️

8/ To establish how well 🩸🧬 cfDNA recapitulates 💉🧬 tumor tissue, we compared the prevalence of mutations between the BTC cfDNA samples (N=1,671) with metastatic BTC tumor NGS data from @AACR Project GENIE (N=349). Correlation was impressively high ⬆️ (R2=0.96)‼️
account_circle